The top-selling class of blood-pressure drugs is under attack from an unusual source: a senior regulator at the Food and Drug Administration.
Dispute flares inside FDA over safety of popular blood-pressure drugs
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.